A 2-Year Study of an Investigational Drug in Obese Patients (0557-011)

Phase 3CompletedNCT00092859

Merck Sharp & Dohme LLC1,500 enrolled

Overview

This is a 2-year study to assess the safety, tolerability, and efficacy of an investigational drug in obese patients.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

1,500

Conditions

Obesity

Interventions

MK0557DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Obese men and nonpregnant women at least 18 years of age with a specific body mass index (height and weight ratio) required by the study Exclusion Criteria: * Patients with uncontrolled high blood pressure and/or diabetes mellitus (high blood sugar)

Outcomes

Primary Outcomes

Body weight after 1 year of treatment. Safety and tolerability for 2 years.

Time frame: After 1 & 2 years of treatment

Secondary Outcomes

Durability of weight loss over two years.

Time frame: Over two years.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.